Risk of disease after isoniazid preventive therapy for mycobacterium tuberculosis exposure in young HIV-uninfected children

Pediatric Infectious Disease Journal

Volumn 34, Issue 11, 2015, Pages 1218-1222

  Luabeya, Kany Kany A ^a   Tameris, Michele D ^a   Geldenhuys, Hennie D ^a   Mulenga, Humphrey ^a   Van Schalkwyk, Amaryl ^a   Hughes, Elizabeth J ^a   Toefey, Asma ^a   Scriba, Thomas J ^a   Hussey, Gregory ^a   Mahomed, Hassan ^b,c   McShane, Helen ^d   Landry, Bernard ^e   Hanekom, Willem A ^a   Hatherill, Mark ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e AERAS   (United States)

Author keywords

Children; IPT; Mycobacterium tuberculosis; Quantiferon TB gold in tube; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BODY WEIGHT; CHILDHOOD DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUBERCULOSIS; COHORT ANALYSIS; NEWBORN; SOUTH AFRICA; STATISTICS AND NUMERICAL DATA;

ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS;

EID: 84944249461     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000874     Document Type: Article

References (25)

1. Marais BJ, Graham SM, Maeurer M, et al. Progress and challenges in childhood tuberculosis. Lancet Infect Dis. 2013;13:287-289.
2. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the prechemotherapy era. Int J Tuberc Lung Dis. 2004;8:392-402.
3. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev. 2007;8:107-117.
4. Moyo S, Verver S, Mahomed H, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. Int J Tuberc Lung Dis. 2010;14:149-154.
5. Ayieko J, Abuogi L, Simchowitz B, et al. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: A meta-analysis. BMC Infect Dis. 2014;14:91.
6. Hill PC, Rutherford ME, Audas R, et al. Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries. PLoS Med. 2011;8:e1001105.
7. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000: CD001363.
8. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334:136.
9. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev. 2009: CD006418.
10. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med. 2012;367:348-361.
11. Schaaf HS, Cotton MF, Boon GP, et al. Isoniazid preventive therapy in HIVinfected and -uninfected children (0-14 years). S Afr Med J. 2013;103:714-715.
12. Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One. 2011;6:e17984.
13. Starke JR. Interferon-γ release assays for the diagnosis of tuberculosis infection in children. J Pediatr. 2012;161:581-582.
14. Tameris MD, Hatherill M, Landry BS, et al; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet. 2013;381:1021-1028.
15. Hawkridge A, Hatherill M, Little F, et al; South African BCG trial team. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ. 2008;337:a2052.
16. Sollai S, Galli L, de Martino M, et al. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: A 2013 update. BMC Infect Dis 2014;14 (Suppl 1):S6.
17. van Soelen N, du Preez K, van Wyk SS, et al. Does an isoniazid prophylaxis register improve tuberculosis contact management in South African children? PLoS One. 2013;8:e80803.
18. Churchyard GJ, Fielding KL, Lewis JJ, et al; Thibela TB Study Team. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370:301-310.
19. Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123:e419-e424.
20. Hesseling AC, Mandalakas AM, Kirchner HL, et al. Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. Thorax. 2009;64:840-846.
21. Marais BJ, Hesseling AC, Schaaf HS, et al. Mycobacterium tuberculosis transmission is not related to household genotype in a setting of high endemicity. J Clin Microbiol. 2009;47:1338-1343.
22. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: A systematic review and meta-analysis. Pediatr Infect Dis J. 2011;30:694-700.
23. Mahomed H, Ehrlich R, Hawkridge T, et al. TB incidence in an adolescent cohort in South Africa. PLoS One. 2013;8:e59652.
24. van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24:1051-1055.
25. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children, 2nd ed. World Health Organization; 2014. Available at: http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748-eng.pdf?ua=1 Accessed November 24, 2014.